Most bugs can't see red—but these beetles can
'To our knowledge, we are the first to have experimentally demonstrated that beetles can actually perceive the color red,' said Johnnes Spaethe, paper co-author and chair of zoology at Germany's University of Würzburg.
Both Pygopleurus chrysonotus and Pygopleurus syriacus are small, fuzzy beetles that belong to the Glaphyridae family, and mostly feed on pollen from red flowering plants like buttercups, anemones, and poppies. This led researchers to wonder how they developed their preferences.
The team utilized a number of methods to determine the two beetles weren't traveling to the red flowers simply due to a UV sensory situation similar to bees. After using a combination of color trapping, behavioral experiments, and electrophysiology, Spaethe and colleagues clearly showed each species includes four types of photoreceptors in their retinas. Aside from UV light, the bugs are able to process blues, greens, and deep reds—although field observations indicated the insects used true color vision to identify and visit red flowers.'The prevailing opinion in science is that flower colors have adapted to the visual systems of pollinators over the course of evolution,' explained Spaethe.
The team's latest findings may complicate this theory, however. In addition to Pygopleurus, two other genera in the larger beetle family (Eulasia and Glaphyrus) display widely different color preferences including red, white, violet, and yellow. This suggests the ability to see red—as well as nature's many other colors—may be relatively more malleable than previously thought.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
BioMed X and Novo Nordisk Launch New Collaboration in Oral Peptide Drug Delivery
Heidelberg, Germany--(Newsfile Corp. - August 19, 2025) - BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Novo Nordisk, a leading global healthcare company headquartered in Denmark. This partnership aims to address one of the most critical challenges in modern drug development: the efficient oral delivery of therapeutic peptides. A research team will be formed to work on this challenge with support from BioMed X and Novo Nordisk. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: BioMed X and Novo Nordisk have launched a joint research project to develop novel oral formulation technologies that enable site-specific, prolonged retention of peptide drugs in the lower small intestine. The initiative aims to overcome key challenges of conventional oral peptide formulations, enhancing bioavailability and continuous release without compromising gastrointestinal safety. BioMed X is inviting scientists worldwide to submit project proposals by October 12, 2025, to join the Heidelberg-based team working on this breakthrough drug delivery technology. Click image above to view full announcement. About BioMed X BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, platform technologies, and artificial intelligence. All our research projects are supported by leading pharmaceutical companies and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research. We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Contacts: Maria Morganti +49 6221 42611 30 mm@ Source: BioMed X To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline
Merck KGaA (NYSE:MRK) is going back on offense in neurologyand it's betting big. The German drugmaker just announced a collaboration with Skyhawk Therapeutics that could top $2 billion, aimed at developing RNA-targeting small molecules for hard-to-treat neurological diseases. Under the deal, Skyhawk will lead discovery and preclinical development using its proprietary RNA splicing tech, while Merck steps in if the science clears early hurdles. Though financial terms weren't disclosed, the structure includes upfront and milestone payments, plus royalties tied to future sales. Warning! GuruFocus has detected 2 Warning Sign with MRK. This isn't a pivot. It's a rebuild. After two major clinical failures rocked its pipeline and with its blockbuster multiple sclerosis drug Mavenclad losing exclusivity starting in 2026, Merck is under pressure to restock its innovation shelf. CEO Belen Garijo is tightening focus on external innovationand fast. That includes this Skyhawk deal, and the recently closed acquisition of SpringWorks Therapeutics, which is expected to start contributing to Merck's healthcare revenue in the second half of this year. Behind the scenes, this deal speaks volumes about where Merck thinks the next frontier lies. Amy Kao, who heads neuroscience and immunology research at Merck, called RNA splicing modulation an exciting frontierand that might be understating it. The company is betting that Skyhawk's tech could unlock new treatments where traditional approaches have failed. If even one program makes it through to commercialization, it could mark a turning point in Merck's quest to reignite long-term growth in its pharma arm. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Map of Earth's functional biosphere reveals 60% of global land area is outside safe zone
A new study on functional biosphere integrity, or the plant kingdom's ability to co-regulate the state of the ecosystem, found that Earth is in trouble—big trouble. Published in the renowned journal One Earth, the study -- led by the Potsdam Institute for Climate Impact Research (PIK) together with BOKU University in Vienna -- investigated whether the plant world is getting enough energy to perform the processes necessary to ensure planetary equilibrium. The majority of the world's land is in a 'precarious state,' according to researchers who mapped the Earth's functional biosphere integrity. That refers to the plant's ability to photosynthesize to maintain the material flows of carbon, water, and nitrogen that support ecosystems. Lead author Fabian Stenzel, member of the PIK research group, emphasized in a press release the enormous need "we have to utilize the biosphere — for food, raw materials and, in the future, also climate protection.' "Our demand for biomass continues to grow, so it's becoming even more critical to quantify the strain we're already putting on the biosphere." Recent research is paving the way to understanding how we're impacting the planet so we can take the necessary and appropriate action steps. How far have we crossed the planet's boundaries? The study builds on the latest update from the Planetary Boundaries framework published in 2023. 'The framework now squarely puts energy flows from photosynthesis in the world's vegetation at the centre of those processes that co-regulate planetary stability', explained Wolfgang Lucht, head of PIK's Earth System Analysis department and coordinator of the study. 'These energy flows drive all of life – but humans are now diverting a sizeable fraction of them to their own purposes, disturbing nature's dynamic processes.' Based on the global biosphere model LPJmL, which simulated water, carbon, and nitrogen flows on a daily basis at a resolution of half a degree of longitude/latitude, the study provides a detailed inventory of each individual year since 1600, the press release continues. According to this model, worrying developments began as early as 1600 in mid-latitudes. The Earth is hurting By 1900, the proportion of global land area where ecosystem changes went beyond the locally defined safe zone, or were even in the high-risk zone, was 37 and 14 percent, respectively, compared to today's 60 and 38 percent, according to the study. In other words, industrialization was already taking a toll, and land use was already putting significant pressure on the Earth's system much earlier than the onset of climate warnings. Right now, researchers can say that the biosphere boundary has been transgressed on almost all land surfaces, mainly due to agriculture. Though the news might sound troubling, researchers describe the map as a 'breakthrough from a scientific perspective' because it reveals the relationship between the human need to extract resources from the environment and the impact that's having. The map concerns itself with 'planetary boundaries,' and it seems they've been crossed. However, the information gleaned provides 'an important impetus for further international climate policy development. This is because it points to the link between biomass and natural carbon sinks, and how they can mitigate climate change. Governments must treat it as a single overarching issue: comprehensive biosphere protection together with strong climate action,' concluded Johan Rockström, PIK Director and one of the co-authors of the study. Read the study in One Earth. Solve the daily Crossword
